Back to Newsroom
Back to Newsroom

SHAREHOLDER ALERT: AHCO ITRM HNST: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Monday, 27 September 2021 05:40 AM

The Law Offices of Vincent Wong

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / September 27, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

AdaptHealth Corp. f/k/a DFB Healthcare Acquisitions Corp. (NASDAQ:AHCO)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/adapthealth-corp-f-k-a-dfb-healthcare-acquisitions-corp-loss-submission-form?prid=19881&wire=1
Lead Plaintiff Deadline: September 27, 2021
Class Period: November 11, 2019 - July 16, 2021

Allegations against AHCO include that: (i) AdaptHealth had misrepresented its organic growth trajectory by retroactively inflating past organic growth numbers without disclosing the changes, in violation of Securities and Exchange Commission regulations; (ii) accordingly, the Company had materially overstated its financial prospects; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Iterum Therapeutics Plc (NASDAQ:ITRM)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=19881&wire=1
Lead Plaintiff Deadline: October 4, 2021
Class Period: November 30, 2020 - July 23, 2021

Allegations against ITRM include that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

The Honest Company, Inc. (NASDAQ:HNST)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/the-honest-company-inc-loss-submission-form?prid=19881&wire=1
Lead Plaintiff Deadline: November 15, 2021
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Honest common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's May 2021 initial public offering.

Allegations against HNST include that: (1) prior to the Initial Public Offering ("IPO"), the Company's results had been significantly impacted by a multimillion-dollar COVID-19 stock-up for products in the Diapers and Wipes category and Household and Wellness category; (2) at the time of the IPO, the Company was experiencing decelerating demand for such products; (3) as a result, the Company's financial results would likely be adversely impacted; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
 

The Law Offices of Vincent Wong, Monday, September 27, 2021, Press release picture

To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

SOURCE: The Law Offices of Vincent Wong

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: